DexCom Reports Officer Changes and Compensation Details

Ticker: DXCM · Form: 8-K · Filed: 2025-10-27T00:00:00.000Z

Sentiment: neutral

Topics: officer-changes, director-changes, compensation, regulation-fd

Related Tickers: DXCM

TL;DR

DexCom filed an 8-K on 10/27 for 10/24 events: officer/director changes & comp. Watch for impacts.

AI Summary

DexCom, Inc. filed an 8-K on October 27, 2025, reporting events on October 24, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes Regulation FD disclosures and financial statements/exhibits.

Why It Matters

This filing indicates potential shifts in leadership or executive compensation at DexCom, which could impact the company's strategic direction and investor confidence.

Risk Assessment

Risk Level: medium — Changes in key officers or directors, especially if accompanied by new compensation structures, can signal strategic shifts or internal dynamics that may affect the company's future performance.

Key Players & Entities

FAQ

What specific officer or director positions were affected by the events reported on October 24, 2025?

The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' but does not specify names or exact roles within this 8-K header.

Are there any new compensatory arrangements for officers detailed in this filing?

Yes, the filing explicitly lists 'Compensatory Arrangements of Certain Officers' as an item of disclosure, suggesting new or updated compensation plans are being reported.

What is the significance of the Regulation FD Disclosure mentioned?

Regulation FD (Fair Disclosure) ensures that material non-public information is disclosed to all investors simultaneously, so this section likely contains information that DexCom is making public to comply with this rule.

Does this filing include any financial statements?

Yes, the filing explicitly states 'Financial Statements and Exhibits' as an item of disclosure, indicating that financial information is being provided.

What is the primary business of DexCom, Inc. based on the SIC code?

DexCom, Inc. is classified under SIC code 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus'.

From the Filing

0001093557-25-000264.txt : 20251027 0001093557-25-000264.hdr.sgml : 20251027 20251027161556 ACCESSION NUMBER: 0001093557-25-000264 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20251024 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251027 DATE AS OF CHANGE: 20251027 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 251420065 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 dxcm-20251024.htm 8-K dxcm-20251024 false 0001093557 0001093557 2025-10-24 2025-10-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 24, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 6340 Sequence Drive , San Diego , CA 92121 (Address of Principal Executive Offices) ( Zip Code) ( 858 ) 200-0200 (Registrant’s Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ITEM 5.02.    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On October 24, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to ten directors and appointed Dr. Euan Ashley as a director, effective immediately. Dr. Ashley will hold office for a term expiring at the 2026 annual meeting of Dexcom’s stockholders (the “2026 Annual Meeting”). The Board also appointed Dr. Ashley to serve as a member of the Nominating and Governance Committee (the “Nominating

View on Read The Filing